Linezolid Kabi

Linezolid, the active ingredient in Linezolid Kabi, is a oxazolidinone presented as an injection for intravenous use. It treats serious bacterial infections such as skin and soft‑tissue infections, community‑acquired and hospital‑acquired pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA).

GNH USA supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic indicated for serious bacterial infections affecting the skin, lungs, and resistant organisms.

- Skin and soft tissue infections: effective against Gram‑positive pathogens, including MRSA, reducing infection severity. - Community‑acquired pneumonia: treats susceptible Streptococcus pneumoniae and other typical agents. - Hospital‑acquired (nosocomial) pneumonia: active against resistant strains causing ventilator‑associated pneumonia. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides bacteriostatic activity against MRSA in various sites.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects: - Myelosuppression: severe decrease in blood cell production, may require monitoring. - Peripheral neuropathy: nerve damage causing tingling or numbness, potentially irreversible. - Lactic acidosis: accumulation of lactate leading to metabolic acidosis, a medical emergency.

Before initiating Linezolid therapy, clinicians should consider several precautionary measures to minimize risk. - Renal impairment: adjust monitoring as accumulation may occur. - Hepatic dysfunction: evaluate liver function tests regularly. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Prolonged therapy (>14 days): monitor blood counts for myelosuppression. - Pregnancy and lactation: use only if benefits outweigh potential unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs), SNRIs, MAO inhibitors: may precipitate serotonin syndrome. - Tyramine‑containing foods and sympathomimetics: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Rifampicin: induces hepatic enzymes, reducing linezolid plasma levels. - Warfarin: may increase INR, requiring closer coagulation monitoring. - Ethanol: potentiates disulfiram‑like reaction, causing flushing and nausea.